Last week’s top five guru bargain stocks were SANDRIDGE ENERGY INC, Cree Inc, Amylin Pharmaceuticals Inc, ICON plc, and Covance Inc. According to GuruFocus updates, these stocks have declined the most since Gurus have bought.
SANDRIDGE ENERGY INC (SD, Financial): Down 25% Since T Boone Pickens Bought In the Quarter Ended on 2010-06-30
T Boone Pickens added to his holdings in Exploration & Production company SANDRIDGE ENERGY INC by 4.95% during the quarter ended 06/30/2010. He owned 1,888,954 shares of as of 06/30/2010. SandRidge Energy, Inc. is an oil and natural gas company headquartered in Oklahoma City with its principal focus on exploration and production. Sandridge Energy Inc has a market cap of $2 billion; its shares were traded at around $5.16 with a P/E ratio of 9.6 and P/S ratio of 3.3.
SD recently reported its third quarter results. Net income available to common stockholders of $297.7 million, or $0.73 per share fully diluted, for third quarter 2010 compared to net loss applicable to common stockholders of $104.1 million, or $0.58 per share fully diluted, in third quarter 2009.
Wallace Weitz bought 4,662,700 shares in the quarter that ended on 06/30/2010, which is 1.49% of the $1.82 billion portfolio of Weitz Wallace R & Co. T Boone Pickens owns 1,888,954 shares as of 06/30/2010, which accounts for 5.29% of the $208 million portfolio of BP Capital.
Prem Watsa owns 3,926,600 shares as of 06/30/2010, a decrease of 39.84% of from the previous quarter. This position accounts for 0.98% of the $2.35 billion portfolio of Fairfax Financial Holdings, Inc.. Arnold Schneider sold out his holdings in the quarter that ended on 06/30/2010.
Sell: Chairman, President & CEO Tom L. Ward sold 6,000,000 shares of SD stock on 10/06/2010 at the average price of 5.86. Tom L. Ward owns at least 21,863,075 shares after this. The price of the stock has decreased by 11.95% since.
Cree Inc. (CREE, Financial): Down 23% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30
Steven Cohen added to his holdings in Semiconductors company Cree Inc. by 581.49% during the quarter ended 06/30/2010. He owned 53,967 shares of as of 06/30/2010. Cree, Inc. is a market-innovator and manufacturer of semiconductors that enhance the value of solid-state lighting, power and communications products by significantly increasing their energy performance and efficiency. Cree Inc. has a market cap of $5.75 billion; its shares were traded at around $54.49 with a P/E ratio of 29.9 and P/S ratio of 6.7. Cree Inc. had an annual average earning growth of 7.5% over the past 10 years.
Cree recently announced record revenue of $268.4 million for its first quarter of fiscal 2011, ended September 26, 2010. This represents a 59% increase compared to revenue of $169.1 million reported for the first fiscal quarter last year and a 1.5% increase compared to the fourth quarter of fiscal 2010. GAAP net income for the first quarter increased 176% year-over-year to $58.0 million, or $0.53 per diluted share, compared to GAAP net income of $21.0 million, or $0.23 per diluted share, for the first quarter of fiscal 2010.
PRIMECAP Management owns 8,522,807 shares as of 06/30/2010, which accounts for 0.93% of the $54.82 billion portfolio of PRIMECAP Management. Mario Gabelli sold out his holdings in the quarter that ended on 06/30/2010.
Sell: EXECUTIVE VICE PRESIDENT, COO Stephen Douglas Kelley sold 26,667 shares of CREE stock on 10/22/2010 at the average price of 49.58. Stephen Douglas Kelley owns at least 28,932 shares after this. The price of the stock has increased by 9.9% since. Other insiders have also decreased their positions in the company.
Amylin Pharmaceuticals Inc. (AMLN, Financial): Down 31% Since Jim Simons Bought In the Quarter Ended on 2010-06-30
Jim Simons added to his holdings in Biotechnology company Amylin Pharmaceuticals Inc. by 3301.53% during the quarter ended 06/30/2010. He owned 445,600 shares of as of 06/30/2010. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin Pharmaceuticals Inc. has a market cap of $1.83 billion; its shares were traded at around $13.05 with and P/S ratio of 2.4.
AMLN recently reported its third quarter 2010 results. The Company reported total revenue of $156.1 million for the third quarter, including net product sales of $154.0 million. GAAP net loss for the quarter ended September 30, 2010 was $50.7 million, or $0.35 per share compared to $26.7 million, or $0.19 per share for the same period in 2009.
Edward Owens owns 1,557,200 shares as of 09/30/2010, which accounts for 0.18% of the $18.12 billion portfolio of Vanguard Health Care Fund. Carl Icahn owns 12,971,328 shares as of 06/30/2010, which accounts for 6.62% of the $0 million portfolio of Icahn Capital Management LP.
ICON plc (ICLR, Financial): Down 28% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30
Steven Cohen added to his holdings in Biotechnology company ICON plc by 31.91% during the quarter ended 06/30/2010. He owned 7,395 shares of as of 06/30/2010. ICON plc is a global full service clinical research organization. Icon Plc has a market cap of $1.23 billion; its shares were traded at around $20.09 with a P/E ratio of 13.8 and P/S ratio of 0.9. Icon Plc had an annual average earning growth of 19.5% over the past 5 years.
George Soros owns 32,400 shares as of 06/30/2010, an increase of 15.3% from the previous quarter. This position accounts for 0.03% of the $3.31 billion portfolio of Soros Fund Management LLC. Jean-Marie Eveillard owns 8,000 shares as of 06/30/2010, a decrease of 42.86% of from the previous quarter. This position accounts for less than 0.01% of the $13.96 billion portfolio of First Eagle Investment Management, LLC.
Covance Inc. (CVD, Financial): Down 21% Since Jeremy Grantham Bought In the Quarter Ended on 2010-06-30
Jeremy Grantham added to his holdings in Biotechnology company Covance Inc. by 79.53% during the quarter ended 06/30/2010. He owned 399,320 shares of as of 06/30/2010. Covance Inc. is a contract research organization providing a wide range of product development services on a worldwide basis to the pharmaceutical, biotechnology and medical device industries. Covance Inc. has a market cap of $2.85 billion; its shares were traded at around $44.38 with a P/E ratio of 18.3 and P/S ratio of 1.4. Covance Inc. had an annual average earning growth of 13.4% over the past 10 years. GuruFocus rated Covance Inc. the business predictability rank of 3-star.
Covance recently reported earnings per diluted share for its second quarter ended June 30, 2010 of $0.49, including $0.09 of facility rationalization and other cost reduction actions during the second quarter, versus $0.60 in the first quarter of 2010 and $0.67 in the second quarter of 2009.
George Soros bought 7,200 shares in the quarter that ended on 06/30/2010, which is 0.01% of the $3.31 billion portfolio of Soros Fund Management LLC. Ron Baron owns 3,111,506 shares as of 06/30/2010, which accounts for 1.13% of the $14.08 billion portfolio of Baron Funds.
Buy: Chairman and CEO Joseph L Herring bought 20,000 shares of CVD stock on 08/02/2010 at the average price of 38.95. Joseph L Herring owns at least 237,202 shares after this. The price of the stock has increased by 13.94% since. There are mixed trades from other insiders.
SANDRIDGE ENERGY INC (SD, Financial): Down 25% Since T Boone Pickens Bought In the Quarter Ended on 2010-06-30
T Boone Pickens added to his holdings in Exploration & Production company SANDRIDGE ENERGY INC by 4.95% during the quarter ended 06/30/2010. He owned 1,888,954 shares of as of 06/30/2010. SandRidge Energy, Inc. is an oil and natural gas company headquartered in Oklahoma City with its principal focus on exploration and production. Sandridge Energy Inc has a market cap of $2 billion; its shares were traded at around $5.16 with a P/E ratio of 9.6 and P/S ratio of 3.3.
SD recently reported its third quarter results. Net income available to common stockholders of $297.7 million, or $0.73 per share fully diluted, for third quarter 2010 compared to net loss applicable to common stockholders of $104.1 million, or $0.58 per share fully diluted, in third quarter 2009.
Wallace Weitz bought 4,662,700 shares in the quarter that ended on 06/30/2010, which is 1.49% of the $1.82 billion portfolio of Weitz Wallace R & Co. T Boone Pickens owns 1,888,954 shares as of 06/30/2010, which accounts for 5.29% of the $208 million portfolio of BP Capital.
Prem Watsa owns 3,926,600 shares as of 06/30/2010, a decrease of 39.84% of from the previous quarter. This position accounts for 0.98% of the $2.35 billion portfolio of Fairfax Financial Holdings, Inc.. Arnold Schneider sold out his holdings in the quarter that ended on 06/30/2010.
Sell: Chairman, President & CEO Tom L. Ward sold 6,000,000 shares of SD stock on 10/06/2010 at the average price of 5.86. Tom L. Ward owns at least 21,863,075 shares after this. The price of the stock has decreased by 11.95% since.
Cree Inc. (CREE, Financial): Down 23% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30
Steven Cohen added to his holdings in Semiconductors company Cree Inc. by 581.49% during the quarter ended 06/30/2010. He owned 53,967 shares of as of 06/30/2010. Cree, Inc. is a market-innovator and manufacturer of semiconductors that enhance the value of solid-state lighting, power and communications products by significantly increasing their energy performance and efficiency. Cree Inc. has a market cap of $5.75 billion; its shares were traded at around $54.49 with a P/E ratio of 29.9 and P/S ratio of 6.7. Cree Inc. had an annual average earning growth of 7.5% over the past 10 years.
Cree recently announced record revenue of $268.4 million for its first quarter of fiscal 2011, ended September 26, 2010. This represents a 59% increase compared to revenue of $169.1 million reported for the first fiscal quarter last year and a 1.5% increase compared to the fourth quarter of fiscal 2010. GAAP net income for the first quarter increased 176% year-over-year to $58.0 million, or $0.53 per diluted share, compared to GAAP net income of $21.0 million, or $0.23 per diluted share, for the first quarter of fiscal 2010.
PRIMECAP Management owns 8,522,807 shares as of 06/30/2010, which accounts for 0.93% of the $54.82 billion portfolio of PRIMECAP Management. Mario Gabelli sold out his holdings in the quarter that ended on 06/30/2010.
Sell: EXECUTIVE VICE PRESIDENT, COO Stephen Douglas Kelley sold 26,667 shares of CREE stock on 10/22/2010 at the average price of 49.58. Stephen Douglas Kelley owns at least 28,932 shares after this. The price of the stock has increased by 9.9% since. Other insiders have also decreased their positions in the company.
Amylin Pharmaceuticals Inc. (AMLN, Financial): Down 31% Since Jim Simons Bought In the Quarter Ended on 2010-06-30
Jim Simons added to his holdings in Biotechnology company Amylin Pharmaceuticals Inc. by 3301.53% during the quarter ended 06/30/2010. He owned 445,600 shares of as of 06/30/2010. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin Pharmaceuticals Inc. has a market cap of $1.83 billion; its shares were traded at around $13.05 with and P/S ratio of 2.4.
AMLN recently reported its third quarter 2010 results. The Company reported total revenue of $156.1 million for the third quarter, including net product sales of $154.0 million. GAAP net loss for the quarter ended September 30, 2010 was $50.7 million, or $0.35 per share compared to $26.7 million, or $0.19 per share for the same period in 2009.
Edward Owens owns 1,557,200 shares as of 09/30/2010, which accounts for 0.18% of the $18.12 billion portfolio of Vanguard Health Care Fund. Carl Icahn owns 12,971,328 shares as of 06/30/2010, which accounts for 6.62% of the $0 million portfolio of Icahn Capital Management LP.
ICON plc (ICLR, Financial): Down 28% Since Steven Cohen Bought In the Quarter Ended on 2010-06-30
Steven Cohen added to his holdings in Biotechnology company ICON plc by 31.91% during the quarter ended 06/30/2010. He owned 7,395 shares of as of 06/30/2010. ICON plc is a global full service clinical research organization. Icon Plc has a market cap of $1.23 billion; its shares were traded at around $20.09 with a P/E ratio of 13.8 and P/S ratio of 0.9. Icon Plc had an annual average earning growth of 19.5% over the past 5 years.
George Soros owns 32,400 shares as of 06/30/2010, an increase of 15.3% from the previous quarter. This position accounts for 0.03% of the $3.31 billion portfolio of Soros Fund Management LLC. Jean-Marie Eveillard owns 8,000 shares as of 06/30/2010, a decrease of 42.86% of from the previous quarter. This position accounts for less than 0.01% of the $13.96 billion portfolio of First Eagle Investment Management, LLC.
Covance Inc. (CVD, Financial): Down 21% Since Jeremy Grantham Bought In the Quarter Ended on 2010-06-30
Jeremy Grantham added to his holdings in Biotechnology company Covance Inc. by 79.53% during the quarter ended 06/30/2010. He owned 399,320 shares of as of 06/30/2010. Covance Inc. is a contract research organization providing a wide range of product development services on a worldwide basis to the pharmaceutical, biotechnology and medical device industries. Covance Inc. has a market cap of $2.85 billion; its shares were traded at around $44.38 with a P/E ratio of 18.3 and P/S ratio of 1.4. Covance Inc. had an annual average earning growth of 13.4% over the past 10 years. GuruFocus rated Covance Inc. the business predictability rank of 3-star.
Covance recently reported earnings per diluted share for its second quarter ended June 30, 2010 of $0.49, including $0.09 of facility rationalization and other cost reduction actions during the second quarter, versus $0.60 in the first quarter of 2010 and $0.67 in the second quarter of 2009.
George Soros bought 7,200 shares in the quarter that ended on 06/30/2010, which is 0.01% of the $3.31 billion portfolio of Soros Fund Management LLC. Ron Baron owns 3,111,506 shares as of 06/30/2010, which accounts for 1.13% of the $14.08 billion portfolio of Baron Funds.
Buy: Chairman and CEO Joseph L Herring bought 20,000 shares of CVD stock on 08/02/2010 at the average price of 38.95. Joseph L Herring owns at least 237,202 shares after this. The price of the stock has increased by 13.94% since. There are mixed trades from other insiders.
